LongevityNext
Argue that consolidation may happen first in care delivery and diagnostics infrastructure rather than pure therapeutics. The piece keeps the focus on evidence, commercial logic, and what would…
Use Abu Dhabi as a regulatory and care-delivery case study. The piece keeps the focus on evidence, commercial logic, and what would make the claim testable.
Argue for layered, organ-specific, trajectory-based biomarkers instead of one clean consumer-facing number. The piece keeps the focus on evidence, commercial logic, and what would make the claim testable.
Use canine lifespan-extension trials as a regulatory test case for longevity medicine. The piece keeps the focus on evidence, commercial logic, and what would make the claim testable.
Not all data is a moat; standardized, repeated, outcome-linked data is. The piece keeps the focus on evidence, commercial logic, and what would make the claim testable.
Menopause, ovarian aging, cardiometabolic risk, bone, brain, and care-delivery models create a bridge between longevity and women's health. The piece keeps the focus on evidence, commercial logic, and…
Dysbiosis sounds compelling, but causality, intervention design, individual variability, and clinical usefulness remain difficult. The piece keeps the focus on evidence, commercial logic, and what would make the…
Clinics need longitudinal outcome tracking, adverse-event capture, standardized reporting, and transparent follow-up. The piece keeps the focus on evidence, commercial logic, and what would make the claim testable.
Evaluate heart-rate variability, sleep, gait, activity, recovery, arrhythmia detection, and the limits of consumer-device data as aging biomarkers. The piece keeps the focus on evidence, commercial logic, and…
Failed or mixed trials define endpoints, populations, dosing, mechanisms, and claim boundaries. The piece keeps the focus on evidence, commercial logic, and what would make the claim testable.